Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 6:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo - injection Clear all
Withdrawn Not applicable Interventional Accepts healthy volunteers

RCT Comparing ESWT With PRP for Plantar Fasciitis in High Demand Cohort

NCT02668510
View directory record Official record
Conditions
Fasciitis, Plantar
Interventions
platelet rich plasma, Normal saline
Biological · Drug
Lead sponsor
Edna Rath
Federal
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Sep 23, 2026, 6:08 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder

NCT03352453
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Rapastinel, Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
17
States / cities
Birmingham, Alabama • Garden Grove, California • Glendale, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Sep 23, 2026, 6:08 PM EDT
Completed Not applicable Interventional Results available

Short-Term Application of Tocilizumab Following Myocardial Infarction

NCT02419937
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Tocilizumab, Placebo
Drug
Lead sponsor
Keesler Air Force Base Medical Center
Federal
Eligibility
18 Years to 89 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Keesler Air Force Base, Mississippi
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 23, 2026, 6:08 PM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

What is the Role of Type III/IV Muscle Afferents in Airway Resistance and Thermoregulatory Responses to Exercise?

NCT07452094
View directory record Official record
Conditions
Placebo - Control, Experimental
Interventions
EXERCISE TRAINING WITH OR WITHOUT MEDICATION
Drug
Lead sponsor
Northern Arizona University
Other
Eligibility
18 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Flagstaff, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 23, 2026, 6:08 PM EDT
Terminated Phase 2 Interventional Results available

Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease

NCT04795466
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Canakinumab, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years to 90 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Charlestown, Massachusetts • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 23, 2026, 6:08 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects

NCT01887366
View directory record Official record
Conditions
Cocaine Addiction
Interventions
TV-1380 150 mg, TV-1380 300 mg, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
14
States / cities
Los Angeles, California • Oceanside, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Sep 23, 2026, 6:08 PM EDT
Completed Not applicable Interventional Results available

Pilot Feasibility Study of the Safety and Efficacy of Anakinra in Heart Failure With Preserved Ejection Fraction

NCT01542502
View directory record Official record
Conditions
Heart Failure
Interventions
Anakinra, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2017 · Synced Sep 23, 2026, 6:08 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction

NCT04463251
View directory record Official record
Conditions
Acute ST Segment Elevation Myocardial Infarction
Interventions
RPH-104 80 mg, Placebo
Biological · Drug
Lead sponsor
R-Pharm Overseas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Cleveland, Ohio • Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 23, 2024 · Synced Sep 23, 2026, 6:08 PM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults

NCT07675629
View directory record Official record
Conditions
HIV Prevention
Interventions
PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C)), PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E)), Alhydrogel adjuvant, GLA-SE adjuvant, Placebo for DNA Vaccines, Protein Vaccines and Adjuvants
Biological
Lead sponsor
Worcester HIV Vaccine
Industry
Eligibility
18 Years to 55 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 23, 2026, 6:08 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

NCT05139602
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Lutikizumab, Placebo
Biological · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 23, 2026, 6:08 PM EDT
Recruiting Phase 2 Interventional

Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus

NCT06964087
View directory record Official record
Conditions
Type I Diabetes
Interventions
OPT101, OPT101 Placebo to Match (PTM)
Drug · Other
Lead sponsor
Op-T LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Birmingham, Alabama • Walnut Creek, California • Aurora, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 23, 2026, 6:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dose Ranging and Dose Frequency of LIPO-102

NCT00918814
View directory record Official record
Conditions
Subcutaneous Adipose Tissue Reduction
Interventions
LIPO-102, Placebo
Drug
Lead sponsor
Neothetics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
San Diego, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 23, 2026, 6:08 PM EDT
Recruiting Phase 1 Interventional

Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation

NCT07076498
View directory record Official record
Conditions
Glioma
Interventions
M032
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
36 Months and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 23, 2026, 6:08 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma

NCT02528214
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo, Oral corticosteroid therapy (prednisone/prednisolone), Inhaled corticosteroid (ICS) therapy, Albuterol/Salbutamol, Levalbuterol/Levosalbutamol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
Los Angeles, California • Rolling Hills Estates, California • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 23, 2026, 6:08 PM EDT
Recruiting Phase 3 Interventional

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

NCT06528314
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions
Efruxifermin, Placebo
Drug
Lead sponsor
Akero Therapeutics, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
2,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
165
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 139 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 23, 2026, 6:08 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Guselkumab in Participants With Active Psoriatic Arthritis

NCT04882098
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Glendale, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 23, 2026, 6:08 PM EDT
Terminated Phase 3 Interventional Results available

Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma

NCT05398263
View directory record Official record
Conditions
Asthma
Interventions
Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
9
States / cities
Newport Beach, California • Denver, Colorado • Newark, Delaware + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 23, 2026, 6:08 PM EDT
Recruiting Phase 2 Interventional

Dupilumab in the Treatment of Pediatric Alopecia Areata

NCT05866562
View directory record Official record
Conditions
Alopecia Areata
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
6 Years to 17 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
5
States / cities
Irvine, California • San Diego, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 23, 2026, 6:08 PM EDT
Not listed Not applicable Interventional

Histology Study of Biostimulatory Activity of Injectable Poly-L-Lactic Acid (Sculptra Aesthetic)

NCT04957446
View directory record Official record
Conditions
Nasolabial Fold, Facial Wrinkles
Interventions
Sculptra Aesthetic, Placebo
Device · Other
Lead sponsor
Sadick Research Group
Other
Eligibility
30 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Sep 23, 2026, 6:08 PM EDT
Completed Phase 2 Interventional Results available

Botulinum Toxin A to Treat Arm Tremor

NCT02207946
View directory record Official record
Conditions
Essential Tremor of the Upper Limbs
Interventions
IncobotulinumtoxinA, Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 23, 2026, 6:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers

NCT05698095
View directory record Official record
Conditions
Pharmacokinetics, Safety, Tolerability
Interventions
5-methoxy-N,N-dimethyltryptamine succinate salt, Placebo
Drug
Lead sponsor
Usona Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Sep 23, 2026, 6:08 PM EDT
Recruiting Phase 3 Interventional

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

NCT06632457
View directory record Official record
Conditions
Metabolic Dysfunction Associated Steatohepatitis
Interventions
Survodutide, Placebo matching survodutide
Combination Product
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
126
States / cities
Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 23, 2026, 6:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese

NCT06445075
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Apitegromab, Placebo, Tirzepatide
Drug
Lead sponsor
Scholar Rock, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
7
States / cities
Chula Vista, California • Orlando, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 23, 2026, 6:08 PM EDT
Completed Phase 3 Interventional

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery

NCT00679588
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Semuloparin Sodium, Enoxaparin sodium, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
4,413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Corlton, California • Huntingdon Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2013 · Synced Sep 23, 2026, 6:08 PM EDT